insulin news from FierceBiotech
News
Sanofi: Acomplia demonstrates better glucose control
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more Read more...
Inhaled insulin lung cancer warning riles investors
The inhaled insulin field got blitzed again today after Nektar Therapeutics and Pfizer reported an increased number of Read more...
Canadian regulators forging new biosimilar pathway
While U.S. lawmakers jawbone about a regulatory pathway for biosimilars, or biogenerics, Read more...
Emisphere chief sees plenty of new potential for technology
When Michael Novinski took over as CEO of Emisphere Technologies, he was acutely aware of just how unsuccessful the developer had been. For 20 years, he tells the Star-Ledger, Emisphere was never Read more...
Alkermes cuts staff after Lilly axes pact
Big Pharma's collective stampede from the inhaled insulin field is claiming the jobs of 150 people who work at Alkermes. The developer said it is cutting 18 percent of its staff due to Read more...
Follow-on legislation follows a twisted path in DC
BIO is toasting proposed new legislation that would provide more than 14 years of patent protection on a biologic. Needless to say, the generics crowd is just a tad disappointed by the bill, saying Read more...
Axial Biotech snares $6M tranche of venture funding
Johnson & Johnson Development Corporation along with vSpring Capital and Ohio Biotech Group have stepped in to provide a $6 million tranche for Axial Biotech's second round of venture capital. Read more...
Insulin retreats blamed for Generex stock drop
Generex is firmly in the camp that sees the glass as half full. After seeing its share price slide 16 percent yesterday, the developer attributed the sudden setback to decisions by Eli Lilly, Read more...
Alkermes: Lilly may dump inhaled insulin program
Alkermes says it wants to push ahead with a broad late-stage study of its inhaled insulin program, even though it believes that Eli Lilly is preparing to pull out of their collaboration deal. Read more...
Novocell reports breakthrough in diabetes cure
Researchers at Novocell report a key breakthrough in their program to find a cure for Read more...
Get more insulin coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends